

Monthly Review of the Impact of the Short-Acting Opioid 7-Day Quantity Limit Policy (Opioid-Naïve Recipients)


Notes:

- 1 The 7-day quantity limit for solid oral dosage forms of short-acting opioids became effective for recipients enrolled in either a Healthy Louisiana MCO plan or Fee for Service on July 10, 2017. This policy applied only to claims/encounters for recipients who were considered opioid-naïve. If the 90-day period prior to an opioid claim/encounter did not include any other opioid claim/encounter, recipients were considered opioid-naïve. When establishing the look back period, day 1 was the date of service of the claim/encounter. Monthly review is performed after the data from MARS Data Warehouse (MDW) is updated to include the previous month.
- 2 This review included paid and adjusted claims/encounters for the short-acting opioids that are included in the 7-day quantity limit policy with dates of service in the previous 24-month period. (December 1, 2016 through November 30, 2018)
- 3 For any particular recipient, this analysis included only those claims/encounters for further evaluation where no previous short-acting or long-acting opioid claim/encounter was identified in the 90-day period before the claim/encounter was submitted.
- 4 Recipients diagnosed with cancer and/or in palliative care at any point in the 24-month review period or in the previous 12 months (December 1, 2015 through November 30, 2018) were excluded from this review. ICD-9 and ICD-10 diagnosis codes associated with medical claims/encounters were included. Lab claims/encounters were excluded.
- 5 Since this review includes only opioid naïve recipients who have not had another opioid prescription in the previous 90 days, the claim count and the unduplicated recipient counts by month are the same.
- 6 Utilization counts for the most current 12-month period are subject to change as claims and encounters with dates of service within the previous 12 months are submitted, paid, or adjusted and subsequently uploaded to the MDW. The results in the last three months of this study are particularly limited by an insufficient lag time.
- 7 Reported payment amounts do not include any potential rebate.

Utilization of Solid Oral Dosage Forms of Short-Acting Opioids in Opioid Naïve Recipients

Date of Service Month-Year	Claim Count	Unduplicated Recipient Count	Payments	Total Units Dispensed	Total Days' Supply	Average Units Dispensed per Claim	Average Days' Supply per Claim
Dec-16	22,283	22,283	\$174,975	578,941	152,649	25.98	6.85
Jan-17	24,496	24,496	\$189,521	634,602	170,680	25.91	6.97
Feb-17	21,833	21,833	\$164,382	547,421	146,202	25.07	6.70
Mar-17	25,326	25,326	\$179,347	593,193	159,665	23.42	6.30
Apr-17	22,294	22,294	\$146,467	465,763	126,309	20.89	5.67
May-17	23,192	23,192	\$151,970	485,053	131,996	20.91	5.69
Jun-17	23,380	23,380	\$156,281	493,234	133,401	21.10	5.71
Jul-17	21,344	21,344	\$141,454	401,351	106,205	18.80	4.98
Aug-17	22,471	22,471	\$162,559	416,531	106,699	18.54	4.75
Sep-17	21,967	21,967	\$128,361	409,977	107,668	18.66	4.90
Oct-17	22,531	22,531	\$127,664	414,638	108,376	18.40	4.81
Nov-17	20,819	20,819	\$115,508	381,984	99,790	18.35	4.79
Dec-17	19,419	19,419	\$106,719	359,058	94,001	18.49	4.84
Jan-18	21,673	21,673	\$123,003	400,021	105,069	18.46	4.85
Feb-18	19,806	19,806	\$105,572	359,454	93,025	18.15	4.70
Mar-18	21,384	21,384	\$110,574	387,687	100,320	18.13	4.69
Apr-18	21,524	21,524	\$112,827	385,313	100,468	17.90	4.67
May-18	21,608	21,608	\$116,469	389,053	101,333	18.01	4.69
Jun-18	21,069	21,069	\$112,820	379,133	99,120	17.99	4.70
Jul-18	21,468	21,468	\$122,617	384,038	100,941	17.89	4.70
Aug-18	22,697	22,697	\$138,654	400,110	105,025	17.63	4.63
Sep-18	19,992	19,992	\$116,833	349,930	92,297	17.50	4.62
Oct-18	21,236	21,236	\$125,979	375,770	98,720	17.69	4.65
Nov-18	12,213	12,213	\$72,693	216,089	57,445	17.69	4.70

Solid Oral Dosage Forms of Short-Acting Opioids for Opioid-Naïve: Average Units Dispensed per Claim



Monthly Review of Antianxiety Benzodiazepine Utilization

Notes:

- 1 Monthly review of benzodiazepine use for anxiety is performed after the MARS Data Warehouse (MDW) is updated to include data from the previous month.
- 2 This review identified paid and adjusted claims/encounters in the MDW for benzodiazepines with dates of service in the previous 24-month period. (December 1, 2016 through November 30, 2018)
- 3 For clonazepam, clorazepate and diazepam, claims/encounters for recipients diagnosed with seizure disorder at any point in the 24-month review period or in the previous 12 months (December 1, 2015 through November 30, 2018) were excluded from this review. ICD-9 and ICD-10 diagnosis codes associated with medical claims/encounters were included. Lab claims/encounters were excluded.
- 4 Utilization counts for the most current 12-month period are subject to change as claims and encounters with dates of service within the previous 12 months are submitted, paid, or adjusted and subsequently uploaded to the MDW. The results in the last three months of this study are particularly limited by an insufficient lag time.
- 5 Reported payment amounts do not include any potential rebate.

Utilization of Benzodiazepines Used in the Treatment of Anxiety

Date of Service Month-Year	Claim Count	Unduplicated Recipient Count	Payments	Total Units Dispensed	Total Days' Supply	Average Units Dispensed per Claim	Average Days' Supply per Claim
Dec-16	29,217	26,623	\$211,979	1,589,525	769,407	54.40	26.33
Jan-17	30,866	28,189	\$225,081	1,657,414	807,181	53.70	26.15
Feb-17	28,329	26,677	\$205,690	1,531,408	742,787	54.06	26.22
Mar-17	33,121	29,649	\$240,171	1,781,771	866,081	53.80	26.15
Apr-17	30,091	28,188	\$215,139	1,626,829	790,376	54.06	26.27
May-17	32,414	29,061	\$234,403	1,746,815	851,958	53.89	26.28
Jun-17	32,157	29,225	\$230,177	1,738,168	845,335	54.05	26.29
Jul-17	31,172	28,817	\$225,644	1,679,134	820,407	53.87	26.32
Aug-17	32,738	29,733	\$258,978	1,754,948	860,581	53.61	26.29
Sep-17	30,679	28,464	\$234,553	1,647,674	807,720	53.71	26.33
Oct-17	31,638	28,963	\$235,862	1,693,782	833,937	53.54	26.36
Nov-17	31,232	28,698	\$230,901	1,676,926	826,067	53.69	26.45
Dec-17	30,097	27,919	\$222,277	1,623,793	799,126	53.95	26.55
Jan-18	30,951	28,230	\$241,759	1,659,480	822,359	53.62	26.57
Feb-18	26,671	25,213	\$192,854	1,450,971	717,089	54.40	26.89
Mar-18	27,781	25,588	\$197,385	1,500,209	744,444	54.00	26.80
Apr-18	28,155	26,196	\$207,373	1,524,451	755,241	54.14	26.82
May-18	29,510	26,822	\$223,000	1,591,026	790,147	53.91	26.78
Jun-18	28,145	26,181	\$215,285	1,516,048	751,921	53.87	26.72
Jul-18	28,869	26,484	\$223,355	1,558,630	771,362	53.99	26.72
Aug-18	30,021	27,153	\$233,765	1,612,753	801,051	53.72	26.68
Sep-18	26,855	25,362	\$205,971	1,441,888	716,311	53.69	26.67
Oct-18	29,617	26,773	\$225,374	1,586,504	789,460	53.57	26.66
Nov-18	17,898	17,174	\$136,860	970,074	480,948	54.20	26.87

Antianxiety Benzodiazepines: Average Units Dispensed per Claim

